Phil has worked closely with our founder for over 7 years and has been involved with all aspects of product, protocol, clinical and pre-commercialization development activities of our products.
Phil is a practicing Registered Pharmacist who has over 30 years of experience in all aspects of the Pharmaceutical Industry with a core expertise in Dermatology products including those focused in Aesthetic Medicine. Phil started his career in Sales with Eli Lilly and Co. Phil went on to hold Executive Sales, Marketing and Administrative positions at Glaxo Inc. (now GSK). Phil first became involved in Dermatology/Aesthetic Medicine while V.P. General Manager North America at ICN Pharmaceuticals (now Valeant) where he managed the Dermatology Portfolio. While at ICN, Phil led the licensing, branding and launch effort of Kinerase®, the most successful single entity cosmetic based line in the U.S. at the time. At ICN, Phil also led the re-introduction of Efudex® after its acquisition from Roche and took sales from $14M to $60M in three years. Phil went on to be President and CEO of Obagi Medical Products (OMPI) where he doubled sales in 2 years and was responsible for adding the Vitamin C and tretinoin based products to the Obagi portfolio, as well as leading major expansions in to Japan and Western Europe. He then went on to be President and CEO of Randall International, then the premier provider of custom amenity and Spa products in the U.S. Phil maintains his own consulting business (Rose and Company) specializing in all aspects of the pre-commercialization planning and commercialization of prescription, OTC and cosmetic based products, with a focus on Dermatology products.
Phil’s knowledge and interest in the pharmacologic applications of fatty acids began as a consultant to Reliant, Inc. The Reliant team developed and marketed the first FDA approved Omega 3 fatty acid product (Fish Oil) to lower HDL cholesterol levels under the brand name Lovaza (Omacor). After reaching annual sales of over $600M, Reliant was sold to GSK.
As a consultant, Phil led the commercialization planning effort in the U.S. for Peplin Inc. with their novel ingenol mebutate compound in development for Rx treatment of Actinic Keratosis. Peplin was acquired by LEO. The product was approved by the FDA in 12/2011 and is marketed by LEO Pharmaceuticals as Picato®. www.picato.com
Phil was co-founder, Chief Marketing Officer and a Board Member of Peninsula Skincare Labs, Inc. Peninsula was founded in March 2011, and developed the novel and patented creatine ascorbate. The company was sold in 2016 and the products are currently marketed as Relevance Skin Fitness.